DNA methyltransferase inhibitors are widely used in preclinical and clinical studies, but poor pharmacokinetics and low efficacy in solid tumors limit their therapeutic use. A new study reports the development and characterization of a specific, non-covalent DNA methyltransferase inhibitor with more-durable DNA hypomethylation and lower toxicity than that of nucleoside analogs.
- Parinaz Mehdipour
- Raymond Chen
- Daniel D. De Carvalho